Premium
Vaccination with β 2 ‐Microglobulin‐Deficient Dendritic Cells Protects Against Growth of β 2 ‐Microglobulin‐Deficient Tumours
Author(s) -
Dammeyer P.,
Mwakigonja A. R.,
Rethi B.,
Chiodi F.,
Wolpert E. Z.
Publication year - 2009
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2009.02270.x
Subject(s) - beta 2 microglobulin , major histocompatibility complex , biology , immunology , antigen , vaccination , transporter associated with antigen processing , histocompatibility , mhc class i , cancer research , human leukocyte antigen
Defects in cell surface expression of major histocompatibility complex class I antigen molecules are common in tumour cells. We have previously described the generation of adaptive immunity to tumour cells deficient in the transporter associated with antigen processing molecule. In this study, we demonstrate enhanced in vivo protection against growth of β 2 ‐microglobulin‐deficient tumour cells in syngeneic C57Bl/6 mice, following vaccination with β 2 ‐microglobulin‐deficient dendritic cells. In vitro analysis suggested that vaccinated mice produced CD3 + cells, which could induce apoptosis in syngeneic β 2 ‐microglobulin‐deficient tumour and non‐malignant cells. Further investigation of target cell recognition suggested that also tumour cells lacking expression of classical major histocompatibility complex class I heavy chains and functional transporter associated with antigen processing molecules were recognized by CD3 + effector cells from vaccinated mice. Histopathological examination of organs from vaccinated mice showed no significant vaccination‐induced pathology. The present findings point to a new possible strategy to counteract the growth of major histocompatibility complex class I‐deficient tumour cells.